Biopool Buys All Shares Held by Zesiger Capital

Biopool International in Ventura announced that as part of the company’s stock-repurchase plan, it has bought all shares held by Zesiger Capital Group of New York City, previously the company’s largest institutional investor.

“Zesiger Capital Group had acquired a total of 1.6 million shares in private placements that took place in May of 1993 and December of 1996,” said Michael D. Bick, Biopool chairman and chief executive officer. “However, they have been a net seller of Biopool stock since early 1998, which has created tremendous downward pressure on the price of Biopool’s common stock.”

Bick said Biopool management believes that the block purchase of all remaining shares held by Zesiger will help reduce the downward pressure on the stock.

Biopool develops test kits to assess and diagnose blood disorders and products used to monitor and measure the presence of drugs. It sells more than 150 Food and Drug Administration-approved products to hospitals, blood-bank facilities, and clinical and reference laboratories.